Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
Robert W. Baird
AddedFeb 11, 2024
UpdatedJul 16, 2026
Robert W. Baird

Robert W. Baird

Operating

Robert W. Baird & Co.: A leading U.S. investment firm offering comprehensive financial services globally.

Location
Milwaukee, WI, US
Founded
1919
Firm
Compare
Portfolio
Employees
Website

Investments

Virtual Incision
Virtual Incision

Total Raised

$146M

Rounds

12

Series C$30MSeptember 2023
Series C$46MNovember 2021
Osano
Osano

Total Raised

$44.4M

Rounds

5

Series B$25MAugust 2023
Parallax
Parallax

Total Raised

$19M

Rounds

3

Series B$12MJanuary 2023
Forj
Forj

Total Raised

$16.5M

Rounds

3

Series Unknown$15MDecember 2022
SeedJuly 2021
High Street Partners
High Street Partners

Total Raised

$36.3M

Rounds

6

Series B$14MDecember 2022
—December 2020
Zylo
Zylo

Total Raised

$71.8M

Rounds

7

Series C$31.5MNovember 2022
Tellius
Tellius

Total Raised

$33M

Rounds

4

Series B$16MOctober 2022
Upfront Healthcare Services
Upfront Healthcare Services

Total Raised

$30.5M

Rounds

4

Series C$10.5MSeptember 2022
Series B$11.5MNovember 2020
Autobooks
Autobooks

Total Raised

$97.8M

Rounds

6

Series C$50MJune 2022
Series A$5.3MJuly 2020
Quiq
Quiq

Total Raised

$44M

Rounds

3

Series C$25MApril 2022
SourceDay
SourceDay

Total Raised

$57.6M

Rounds

6

Series C$31.5MFebruary 2022
Circonus
Circonus

Total Raised

$16.8M

Rounds

3

Series B$10MNovember 2021
Vodori
Vodori

Total Raised

$11M

Rounds

3

Series A$7.5MSeptember 2021
Strata Oncology
Strata Oncology

Total Raised

$128M

Rounds

3

Series C$90MJuly 2021
Saranas
Saranas

Total Raised

$29.2M

Rounds

8

Series B$12.8MJuly 2021
Crayon
Crayon

Total Raised

$38.1M

Rounds

6

Series B$22MMay 2021
ChurnZero
ChurnZero

Total Raised

$34.5M

Rounds

3

Series B$25MMarch 2021
Tracer
Tracer

Total Raised

$29.6M

Rounds

5

Series C$12.2MJanuary 2021
Jumpcode Genomics
Jumpcode Genomics

Total Raised

$23.5M

Rounds

2

Series B$21MJanuary 2021
OncoHealth
OncoHealth

Total Raised

$56.5M

Rounds

4

Series C$28MMay 2020